Price$1.23-2.47 (-66.76%)
2026-05-212026-08-25
News · 26 weeks58-20%
2026-03-012026-08-23
Mix2690d
- Other13(50%)
- SEC Filings10(38%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form S-3 filed by Co-Diagnostics Inc.S-3 - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Participates in Medical Devices and Innovations Roundtable Media EventCompany Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UTSALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated by the intellectual property law firm Maschoff Brennen in Salt Lake City, Utah.
- SECSEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)
- SECSEC Form 10-Q filed by Co-Diagnostics Inc.10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Reports Second Quarter 2026 Financial ResultsAdvancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing ExpansionStrengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled CapabilitiesSALT LAKE CITY, Aug. 13, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights:Advanced CoMira Diagnostics' manufacturing strategy in the Kin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Co-Diagnostics Inc.SCHEDULE 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
- PRCo-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care TestSubmission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settingsSALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration ("FDA") for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument*. The submission follows the Company's previously anno
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Announces Second Quarter 2026 Earnings Release Date and WebcastSALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
- PRCo-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical StudiesCompany also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrumentSALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms ("C-CAMP"), an initiative supported by the India Department of Biotechnology.
- SECCo-Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
- SECSEC Form 424B5 filed by Co-Diagnostics Inc.424B5 - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR PlatformPCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across IndiaSALT LAKE CITY, July 22, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro® instrument. The initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform*, following the Company's previously an
- SECSEC Form DEF 14A filed by Co-Diagnostics Inc.DEF 14A - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific OfficerSALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University. Over his career, Dr. Lindsey has led assay development and R&D teams that produced more than a dozen FDA 510(k)
- SECSEC Form PRE 14A filed by Co-Diagnostics Inc.PRE 14A - Co-Diagnostics, Inc. (0001692415) (Filer)
- PRCo-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, ThailandInvited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partnerWorkshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnosticsSALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NP
- PRCo-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care TestMore than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runsAnalytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® inst
- PRCo-Diagnostics Vector Smart® Division Expands Footprint to 21 StatesExpansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement district ("MAD") customer base for the Vector Smart® line of products and services have grown to include MADs in 21 states, with four new full laboratory installs added in June alone. The announcement coincides with Co-Dx hosting a webinar for prospective MAD customers in recognition
- PRCo-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing LineVisit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer SALT LAKE CITY, June 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that a delegation from CoMira Diagnostics ("CoMira"), the Company's joint venture with partners in the Kingdom of Saudi Arabia ("KSA"), visited Co-Diagnostics' Salt Lake City headquarters ahead of a planned technology transfer to CoMira. The visit included a tour of the Company's facilities and unveiling a future automated manufacturing
- PRCo-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor AgreementLongstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu of molecular diagnostics products across a key Latin American marketSALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR point-of-care platform*, including the PCR Pro® instrument and associated test kits, advancing the Company's strategy to expand its commercialization network and footprin
- SECSEC Form SCHEDULE 13G filed by Co-Diagnostics Inc.SCHEDULE 13G - Co-Diagnostics, Inc. (0001692415) (Subject)
- PRCo-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform CapabilitiesDual-assay strategy designed to support outbreak response and surveillance efforts in affected regionsPotential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-care platform capabilitiesSALT LAKE CITY, June 2, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics Pvt. Ltd. ("CoSara" or the "JV"). The program includes development of both a pan-Ebola assay designed to rapidly detect multiple ebolavirus sp
- SECSEC Form EFFECT filed by Co-Diagnostics Inc.EFFECT - Co-Diagnostics, Inc. (0001692415) (Filer)
CODX FAQ
7 questionsWhat does Co-Diagnostics Inc. do?
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant...Where does CODX stock trade?
Co-Diagnostics Inc. (CODX) is listed on NASDAQ.What sector and industry is CODX in?
Co-Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Co-Diagnostics Inc. go public?
Co-Diagnostics Inc. (CODX) completed its IPO in 2026.What are analysts saying about CODX?
Co-Diagnostics Inc. has had 3 recent analyst actions on file. The most recent action was from Sidoti: Neutral with a $500.00 price target on 2022-08-12. Recent price targets range from $500.00 to $1500.00.What companies are similar to CODX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CODX side-by-side with any of them on Quantisnow.How can I track CODX on Quantisnow?
Quantisnow aggregates Co-Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CODX to receive live email and push alerts on every new disclosure.